Search

Your search keyword '"Weisman, M. H."' showing total 296 results
Start Over Author "Weisman, M. H."
296 results on '"Weisman, M. H."'

3. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

Author

Clegg, D O, Reda, D J, Harris, C L, Klein, M A, O'Dell, J R, Hooper, M M, Bradley, J D, Bingham, C O, Weisman, M H, Jackson, C G, Lane, Nancy E, Cush, J J, Moreland, L W, Schumacher, H R, Oddis, C V, Wolfe, F, Molitor, J A, Yocum, D E, Schnitzer, T J, Furst, D E, Sawitzke, A D, Shi, H, Brandt, K D, Moskowitz, R W, and Williams, H J

Abstract

BACKGROUND: Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis. METHODS: We randomly assigned 1583 patients with symptomatic knee osteoarthritis to receive 1500 mg of glucosamine daily, 1200 mg of chondroitin sulfate daily, both glucosamine and chondroitin sulfate, 200 mg of celecoxib daily, or placebo for 24 weeks. Up to 4000 mg of acetaminophen daily was allowed as rescue analgesia. Assignment was stratified according to the severity of knee pain (mild [N=1229] vs. moderate to severe [N=354]). The primary outcome measure was a 20 percent decrease in knee pain from baseline to week 24. RESULTS: The mean age of the patients was 59 years, and 64 percent were women. Overall, glucosamine and chondroitin sulfate were not significantly better than placebo in reducing knee pain by 20 percent. As compared with the rate of response to placebo (60.1 percent), the rate of response to glucosamine was 3.9 percentage points higher (P=0.30), the rate of response to chondroitin sulfate was 5.3 percentage points higher (P=0.17), and the rate of response to combined treatment was 6.5 percentage points higher (P=0.09). The rate of response in the celecoxib control group was 10.0 percentage points higher than that in the placebo control group (P=0.008). For patients with moderate-to-severe pain at baseline, the rate of response was significantly higher with combined therapy than with placebo (79.2 percent vs. 54.3 percent, P=0.002). Adverse events were mild, infrequent, and evenly distributed among the groups. CONCLUSIONS: Glucosamine and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee. Exploratory analyses suggest that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain.

Published
2006

4. Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes

Author

Monti, S., Craven, A., Klersy, C., Montecucco, C., Caporali, R., Watts, R., Merkel, P. A., Luqmani, R., Achilleos, K., Adler, M., Alba, M. A., Albert, D. A., Alibaz-Oner, F., Allcoat, P., Amano, K., Amarasuriya, M., Amudala, N. A., Andrews, J., Archer, A. M., Arimura, Y., Atukorala, I., Azevedo, E., Bajad, S., Baldwin, C., Barra, L. J., Baslund, B., Basu, N., Baykal, M., Berger, C., Berglin, E., Besada, E., Bhardwaj, M., Bischof, A., Blockmans, D., Blood, J., Draibe, J. B., Brand, S., Brandao, M., Bruce, I. N., Butler, A., Calabrese, L. H., Ferrer, D. C., Carette, S., Carmona, D., Ceunen, H., Chakravarty, K., Chapman, P. T., Chocova, Z., Chung, S. A., Ci, W., Cid, M. C., Clark, T. M., Clarkson, M. R., De Jesus Contreras-Rodriguez, F., Conway, R., Cooke, K., Viros, X. C., Cordeiro, A., Costa, A., Culfear, K., Daikeler, T., Danda, D., Das, S. K., Dasgupta, B., De Castro, A. M., Dehghan, N., Devassy, R., Dhindsa, N., Diamantopoulos, A. P., Direskeneli, H., Dobashi, H., Juan, D., Durrani, M., Edelsten, C., Eifert, J., Elhayek, S., Elsideeg, S., Endo, T., Erden, A., Erer, B., Eriksson, P., Erturk, Z., Espigol-Frigole, G., Felicetti, M., Ferraro, A., Ferro, J. M., Fifi-Mah, A., Flores-Suarez, L. F., Flossmann, O., Flynn, D., Fonseca, J. E., Foot, J., Foote, M., Forbess, L., Fujimoto, S., Fukuoka, K., Furtado, C., Furuta, S., Gaffo, A. L., Gallagher, P., Gao, N., Gatenby, P., Gendi, N., Geraldes, R., Gerits, A., Gioffredi, A., Gomples, L., Goncalves, M. J., Gondo, P., Graham, A., Grainger, R., Gray, D. T., Grayson, P. C., Griffiths, L., Guo, Y., Gupta, R., Gylling, M., Hajj-Ali, R. A., Hammam, N., Harigai, M., Hartley, L., Haslett, J., Hassan, A., Hatemi, G., Hellmich, B., Henckaerts, L., Henes, J. C., Hepburn, J., Herd, V., Hess, C., Hill, C., Hinojosa-Azaola, A., Hirahashi, J., Hirano, F., Hocevar, A., Holle, J., Hollinger, N., Homma, S., Howard, T., Hoyles, R. K., Hruskova, Z., Hutcheon, G., Ignacak, M., Igney-Oertel, A., Ikeda, K., Ikegaya, N., Jagadeesh, S., Jaquith, J., Jayne, D. R. W., Jewell, T., Jones, C., Joshi, A., Kalyoncu, U., Kamall, S., Kamath, S., Lai, K. S., Kaname, S., Kanchinadham, S., Karadag, O., Karube, M., Kaszuba, M., Kaur, R., Kawakami, T., Kawashima, S., Khalidi, N., Khan, A., Kikuchi, M., Kilic, L., Kimura, M., King, M. J., Klapa, S., Klocke, R., Kobayashi, T., Kobayashi, S., Komagata, Y., Kronbichler, A., Kuczia, P., Kumar, M. S., Kurosawa, M., Lamprecht, P., Langford, C. A., Lanyon, P., Laversuch, C., Lee, S. J., Leoni, S., Li, J., Liang, K., Liang, P., Liao, H., Lee, L. A., Luqmani, R. A., Lyle, A., Macdonald, M., Mackie, S. L., Madden, L., Magliano, M., Makino, H., Makol, A., Malaiya, R., Malaviya, A., Manthri, R., Maritati, F., Da Silva, A. M., Mason, J. C., Matara, C., Matsui, K., Matteson, E. L., Mcbride, D., Mccullough, K., Mcgeoch, L., Mclaren, J., Mcmillian, C., Mendiratta, N., Menon, A., Merinopoulos, D., Merkel, P., Messier, S., Micheletti, R. G., Mills, K., Milman, N., Minoda, M., Minz, R. W., Mock, C., Mohammad, A. J., Moiseev, S., Moitinho, M., Molloy, E., Monach, P. A., Montgomery, M., Moosig, F., Moradizadeh, M., Morgan, M., Morgan, A. W., Morgan, A. -M., Muir, A., Mukhtyar, C., Muller, A., Muratore, F., Muso, E., Nada, R., Nakajima, H., Nakajima, T., Nakano, H., Nandagudi, A., Neumann, T., Y. F., Ng, K. H., Ng, Nogueira, E. L., Nolkha, N., Nordstrom, D., Novikov, P., Nugaliyadde, A., O'Donnell, J. L., O'Donoghue, J., O'Neill, L., O'Riordan, E., Oatley, M., Okubo, K., Oliva, E., Oshikawa, H., Ota, Y., Padoan, R., Pagnoux, C., Pan, L., Panaritis, K., Park, J. K., Patel, S., Patil, P., Pazzola, G., Peall, A., Pearce, F., Pehlevan, S., Pereira, L., Pettersson, T., Pineau, C. A., Pirila, L., Poglodek, B., Ponte, C., Prieto-Gonzalez, S., Priya, S. R., Purewal, B., Purschke, S., Putaala, J., Quickert, S., Quincey, V., Raghuvanshi, S., Rajasekhar, L., Ranganathan, D., Rathi, M., Rees, D., Rees, F., Renken, U., Restuccia, G., Rhee, R. L., Rice, B., Robins, D., Robson, J., Rodrigues, M., Romao, V. C., Rotar, C., Ruediger, C., Rutgers, A., A. C., Sa, Saavedra, M. J., Sada, K. -E., Sahbudin, I., Salvarani, C., Sandhu, N., Santos, E., Sato, Y., Schafer, V. S., Schiavon, F., Schmidt, W. A., Segelmark, M., Shahin, A., Sharma, A., Shotton, J., Silva, C., Singer, O. G., Sivasuthan, G., Smolen, S., Solanich-Moreno, X., Boixader, L. S., Song, Y. W., Springer, J., Sreih, A. G., Srivastava, R., Stamp, L. K., Stevens, R., Strbian, D., Sugino, K., Sunderkotter, C., Suppiah, R., Suzuki, K., Szekanecz, Z., Sznajd, J., Taimen, K., Tak, P. P., Takeuchi, T., Takizawa, N., Tames, L., Tan, B. E., Tanaka, M., Tang, M. W., Tatlisumak, T., Tesar, V., Thomas, A., Tian, X., Tokunaga, K., Tombetti, E., Tomsic, M., Toz, B., Tsukamoto, T., Uchida, S., Unal, A. U., Urban, M. L., Usui, J., Vaglio, A., Venkatachalam, S., Vermaak, E., Viswanath, V., Wada, T., Wagh, S., Wallace, D. J., Walters, G., Walz, B., Wan, J., Wang, T., Wang, G., Warrington, K. J., Watts, R. A., Wawrzycka-Adamczyk, K., Weeratunga, P., Weisman, M. H., Wickramasinghe, S., Williams, M., Wojcik, K., Woodruff, L., Xenitidis, T., Yamada, H., Yamagata, K., Yee, C. -S., Yoon, M., Yoshida, K., Yoshifuji, H., Ytterberg, S. R., Yumura, W., Zayed, H., Zeng, X., Zhao, M. -H., Zugaj, A., Zuk, J., İç Hastalıkları, Clinical Haematology, and Translational Immunology Groningen (TRIGR)

Subjects
Male, Outcome, Antineutrophil Cytoplasmic, 030232 urology & nephrology, 0302 clinical medicine, Risk Factors, 80 and over, Pharmacology (medical), Age of Onset, Young adult, Aged, 80 and over, education.field_of_study, age, anti-neutrophil cytoplasmic antibody-associated vasculitis, outcome, Adolescent, Adult, Aged, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antibodies, Antineutrophil Cytoplasmic, Female, Humans, Middle Aged, Morbidity, Prognosis, Retrospective Studies, Risk Assessment, Survival Rate, United Kingdom, Young Adult, Vasculitis, Systemic vasculitis, medicine.medical_specialty, Population, anti-neutrophil cytoplasmic antibody–associated vasculitis, Antibodies, 03 medical and health sciences, Rheumatology, Internal medicine, medicine, education, Anti-neutrophil cytoplasmic antibody–associated vasculitis, Survival rate, Anti-neutrophil cytoplasmic antibody, 030203 arthritis & rheumatology, business.industry, Retrospective cohort study, medicine.disease, Age of onset, business
Abstract

Objectives ANCA-associated vasculitis (AAV) can affect all age groups. We aimed to show that differences in disease presentation and 6 month outcome between younger- and older-onset patients are still incompletely understood. Methods We included patients enrolled in the Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study between October 2010 and January 2017 with a diagnosis of AAV. We divided the population according to age at diagnosis: Results A total of 1338 patients with AAV were included: 66% had disease onset at Conclusion Within 6 months of diagnosis of AAV, patients >65 years of age display a different pattern of organ involvement and an increased risk of significant damage and mortality compared with younger patients.

Published
2021
Full Text
View/download PDF

5. Bacterial native joint arthritis

Author

Hochberg, Marc C, Gravallese, Ellen M, Smolen, Josef S, van der Heijde, Désirée; https://orcid.org/0000-0002-5781-158X, Weinblatt, Michael E, Weisman, Michael H, Hochberg, M C ( Marc C ), Gravallese, E M ( Ellen M ), Smolen, J S ( Josef S ), van der Heijde, D ( Désirée ), Weinblatt, M E ( Michael E ), Weisman, M H ( Michael H ), Kronberger, Leo R W, Obenhuber, Tilman, Uçkay, Ilker; https://orcid.org/0000-0002-5552-0973, Hochberg, Marc C, Gravallese, Ellen M, Smolen, Josef S, van der Heijde, Désirée; https://orcid.org/0000-0002-5781-158X, Weinblatt, Michael E, Weisman, Michael H, Hochberg, M C ( Marc C ), Gravallese, E M ( Ellen M ), Smolen, J S ( Josef S ), van der Heijde, D ( Désirée ), Weinblatt, M E ( Michael E ), Weisman, M H ( Michael H ), Kronberger, Leo R W, Obenhuber, Tilman, and Uçkay, Ilker; https://orcid.org/0000-0002-5552-0973

Published
2022

38. Minimally invasive procedures

Author

Gerlag, Danielle M., Tak, Paul-Peter, Hochberg, Marc C., Silman, Alan J., Smolen, Josef S., Weinblatt, Michael E., Weisman, M. H., Amsterdam institute for Infection and Immunity, and Clinical Immunology and Rheumatology

Published
2011

40. Anti-C1q antibodies in systemic lupus erythematosus

Author

Orbai, A-M, Truedsson, L, Sturfelt, G, Nived, O, Fang, H, Alarcón, G S, Gordon, C, Merrill, Jt, Fortin, P R, Bruce, I N, Isenberg, D A, Wallace, D J, Ramsey-Goldman, R, Bae, S-C, Hanly, J G, Sanchez-Guerrero, J, Clarke, A E, Aranow, C B, Manzi, S, Urowitz, M B, Gladman, D D, Kalunian, K C, Costner, M I, Werth, V P, Zoma, A, Bernatsky, S, Ruiz-Irastorza, G, Khamashta, M A, Jacobsen, Søren, Buyon, J P, Maddison, P, Dooley, M A, Van Vollenhoven, R F, Ginzler, E, Stoll, T, Peschken, C, Jorizzo, J L, Callen, J P, Lim, S S, Fessler, B J, Inanc, M, Kamen, D L, Rahman, A, Steinsson, K, Franks, A G, Sigler, L, Hameed, S, Pham, N, Brey, R, Weisman, M H, McGwin, G, Magder, L S, Petri, M, Orbai, A-M, Truedsson, L, Sturfelt, G, Nived, O, Fang, H, Alarcón, G S, Gordon, C, Merrill, Jt, Fortin, P R, Bruce, I N, Isenberg, D A, Wallace, D J, Ramsey-Goldman, R, Bae, S-C, Hanly, J G, Sanchez-Guerrero, J, Clarke, A E, Aranow, C B, Manzi, S, Urowitz, M B, Gladman, D D, Kalunian, K C, Costner, M I, Werth, V P, Zoma, A, Bernatsky, S, Ruiz-Irastorza, G, Khamashta, M A, Jacobsen, Søren, Buyon, J P, Maddison, P, Dooley, M A, Van Vollenhoven, R F, Ginzler, E, Stoll, T, Peschken, C, Jorizzo, J L, Callen, J P, Lim, S S, Fessler, B J, Inanc, M, Kamen, D L, Rahman, A, Steinsson, K, Franks, A G, Sigler, L, Hameed, S, Pham, N, Brey, R, Weisman, M H, McGwin, G, Magder, L S, and Petri, M

Abstract

OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.RESULTS: Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).CONCLUSIONS: Anti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.

Published
2015

43. Anti-C1q antibodies in systemic lupus erythematosus

Author

Orbai, A-M, primary, Truedsson, L, additional, Sturfelt, G, additional, Nived, O, additional, Fang, H, additional, Alarcón, G S, additional, Gordon, C, additional, Merrill, JT, additional, Fortin, P R, additional, Bruce, I N, additional, Isenberg, D A, additional, Wallace, D J, additional, Ramsey-Goldman, R, additional, Bae, S-C, additional, Hanly, J G, additional, Sanchez-Guerrero, J, additional, Clarke, A E, additional, Aranow, C B, additional, Manzi, S, additional, Urowitz, M B, additional, Gladman, D D, additional, Kalunian, K C, additional, Costner, M I, additional, Werth, V P, additional, Zoma, A, additional, Bernatsky, S, additional, Ruiz-Irastorza, G, additional, Khamashta, M A, additional, Jacobsen, S, additional, Buyon, J P, additional, Maddison, P, additional, Dooley, M A, additional, Van Vollenhoven, R F, additional, Ginzler, E, additional, Stoll, T, additional, Peschken, C, additional, Jorizzo, J L, additional, Callen, J P, additional, Lim, S S, additional, Fessler, B J, additional, Inanc, M, additional, Kamen, D L, additional, Rahman, A, additional, Steinsson, K, additional, Franks, A G, additional, Sigler, L, additional, Hameed, S, additional, Pham, N, additional, Brey, R, additional, Weisman, M H, additional, McGwin, G, additional, Magder, L S, additional, and Petri, M, additional

Published
2014
Full Text
View/download PDF

45. The pathogenesis of Ankylosing spondylitis

Author

Weisman, M H, Reveille, J D, van der Heijde, D, Reveille, John, Brown, Matthew, Weisman, M H, Reveille, J D, van der Heijde, D, Reveille, John, and Brown, Matthew

Published
2006

49. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

Author

Furst, D E, primary, Keystone, E C, additional, Fleischmann, R, additional, Mease, P, additional, Breedveld, F C, additional, Smolen, J S, additional, Kalden, J R, additional, Braun, J, additional, Bresnihan, B, additional, Burmester, G R, additional, De Benedetti, F, additional, Dorner, T, additional, Emery, P, additional, Gibofsky, A, additional, Kavanaugh, A, additional, Kirkham, B, additional, Schiff, M H, additional, Sieper, J, additional, Singer, N, additional, Van Riel, P L C M, additional, Weinblatt, M E, additional, Weisman, M H, additional, and Winthrop, K, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results